Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Feb 12:3:59.
doi: 10.1186/1757-1626-3-59.

Interstitial lung disease associated to erlotinib treatment: a case report

Yolanda Del Castillo  1 , Paulina Espinosa, Fernanda Bodí, Raquel Alcega, Emma Muñoz, Carlos Rabassó, David Castander
Affiliations

Interstitial lung disease associated to erlotinib treatment: a case report

Yolanda Del Castillo et al. Cases J. .

Abstract

Introduction: Few cases of pulmonary toxicity related to epidermal growth factor receptor-targeted agents have been described.

Case presentation: We report a case of a 63-year-old white male with stage IV non-small cell lung cancer treated with erlotinib who developed a interstitial lung disease.

Conclusion: Respiratory symptoms during treatment with erlotinib should alert clinicians to rule out pulmonary toxicity. Early erlotinib withdrawal and corticoid administration were successful.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Diffuse bilateral interstitial infiltrates were predominant in upper lobes. Right hiliar consolidation corresponds to the tumor.
Figure 2
Figure 2
Pulmonary CT scan shows extensive ground glass opacities.
Figure 3
Figure 3
(Six days later) important reduction of the bilateral infiltrates; previous consolidation is still present.
Figure 4
Figure 4
(Three months later) a CT scan shows almost complete resolution with minimal residual reticular opacities in the right lung.
See this image and copyright information in PMC

References

    1. Marshall J. Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer. 2006;107:1207–1218. doi: 10.1002/cncr.22133. - DOI - PubMed
    1. Blackledge G, Averbuch S. Gefitinib (Iressa, ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004;90(3):566–572. doi: 10.1038/sj.bjc.6601550. - DOI - PMC - PubMed
    1. Bunn PA Jr, Thatcher N. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction. Oncologist. 2008;13(Suppl 1):1–4. doi: 10.1634/theoncologist.13-S1-1. - DOI - PubMed
    1. Liu V, White DA, Zakowski MF, Travis W, Kris MG, Ginsberg MS, Miller VA, Azoli CG. Pulmonary toxicity associated with erlotinib. Chest. 2007;132:1042–1044. doi: 10.1378/chest.07-0050. - DOI - PubMed
    1. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, LeGall JR, Morris A, Spragg R. Report of the American-European consensus conference on ARDS: definitions, mechanisms, relevant outcomes and clinical trial coordination. The Consensus Committee. Intensive Care Med. 1994;20(3):225–32. doi: 10.1007/BF01704707. - DOI - PubMed

LinkOut - more resources